Craft

Ocular Therapeutix

Stock Price

$11.3

2024-10-29

Market Capitalization

$1.8 B

2024-10-29

Revenue

$52 M

FY, 2025

Ocular Therapeutix Summary

Company Summary

Overview
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company's products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.
Type
Public
Status
Active
Founded
2006
HQ
Bedford, MA, US | view all locations
Website
http://www.ocutx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Antony Mattessich

    Antony Mattessich, President, Chief Executive Officer and Director

  • Scott Corning

    Scott Corning, Senior Vice President of Commercial

  • Karen-Leigh Edwards

    Karen-Leigh Edwards, Senior Vice President of Technical Operations

  • Peter Jarrett

    Peter Jarrett, Chief Scientific Officer

LocationsView all

3 locations detected

  • Bedford, MA HQ

    United States

    24 Crosby Dr

  • Bedford, MA

    United States

    15 Crosby Dr

  • Bedford, MA

    United States

    36 Crosby Dr

Ocular Therapeutix Financials

Summary Financials

Revenue (Q1, 2026)
$10.8M
Gross profit (Q1, 2026)
$9.5M
Net income (Q1, 2026)
($88.6M)
Cash (Q1, 2026)
$666.7M
EBIT (Q1, 2026)
($93.3M)
Enterprise value
$1.2B

Footer menu